Last reviewed · How we verify
NCT06680895
FeNO Observation Study in ICU Patients With ARS
trial testing FeNO Observation in Compare the Concentration of Exhaled Nitric Oxide in Patients With Different Severity of RF in 1,000 participants. Currently enrolling.
30 September 2025
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 July 2024 |
| Primary completion | 30 September 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- FeNO Observation
Conditions studied
- Compare the Concentration of Exhaled Nitric Oxide in Patients With Different Severity of RF — all drugs for Compare the Concentration of Exhaled Nitric Oxide in Patients With Different Severity of RF →
Sponsor
Shanghai Zhongshan Hospital
Who can join
Adults 18 to 80, any sex, with Compare the Concentration of Exhaled Nitric Oxide in Patients With Different Severity of RF. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. Main Objective: To compare the concentration of exhaled nitric oxide in patients with different severity of respiratory failure in ICU. 2. Secondary Purpose: 1. To observe the change of nitric oxide concentration in exhaled breath of patients with mechanical ventilation over time; 2. The relationship and differences between pulmonary ventilation blood flow levels in patients with different exhaled NO concentrations; 3. Reactivity of patients with different exhaled NO concentrations to inhaled nitric oxide therapy and the relationship between them.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06680895
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06680895 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 8 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06680895.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing